Introduction
The use of cell transplantation for brain repair depends on neural progenitors that retain their ability to proliferate, migrate, and differentiate to repopulate areas of lesions. A first step in designing cell repair strategies is to analyze the developmental properties of specific neural progenitor populations, to identify intrinsic mechanisms that could be exploited to promote cell regeneration by using endogenous or grafted cells.
The postnatal brain contains populations of progenitors that display different proliferative and migratory potentials. The most extensively characterized are those found in the subventricular zone (SVZ) (Doetsch et al., 1999 (Doetsch et al., , 2002 and in the dentate gyrus (Gage, 2000) . One class of progenitors in these areas expresses the proteoglycan NG2. NG2 ϩ cells are the most numerous progenitor population of the postnatal brain (Dawson et al., 2000) and can be either highly proliferative and migratory, such as in the SVZ, or slowly dividing and nonmigratory, such as in the cerebral cortex and olfactory bulb (OB) . We have demonstrated previously that SVZ NG2 ϩ cells isochronically transplanted into the lateral ventricle (LV) proliferate and migrate caudally to the hippocampus and subcortical white matter (SCWM) and to the OB via the rostral migratory stream (RMS) . Conversely, grafted cortical NG2 ϩ cells neither proliferate nor migrate out of the LV . These findings raise important questions about the intrinsic properties that render a progenitor cell proliferative and migratory and provide the opportunity to define signaling molecules that may promote proliferation and migration in quiescent neural progenitors.
Several molecular signals have been implicated in neuroblast tangential migration, including the following: (1) the polysialylated form of the neural cell-adhesion molecule, which confers a migratory phenotype to neuroblasts (Pencea and Luskin, 2003) ; (2) deleted in colorectal carcinoma and integrins, which mediate directional migration of neural precursors (Murase and Horwitz, 2002) ; (3) the soluble ligands Slit1 and Slit2, as guidance signals (Bagri et al., 2002) , and (4) members of the receptor tyrosine kinase family (RTK), which includes the Eph family and their transmembrane-associated ephrin ligands (Conover et al., 2000) and members of the Erb RTK family, particularly Erb4 and its ligand neuregulin (Anton et al., 2004; Corfas et al., 2004; Flames et al., 2004) . The Erb RTK family also includes the epidermal growth factor receptor (EGFR) (Erb1) and its ligand EGF, which play an important role in the proliferation and maintenance of embryonic and adult neural stem cells (Doetsch et al., 1999 (Doetsch et al., , 2002 Gage, 2000; Junier, 2000; Yarden and Sliwkowski, 2001 ). The EGFR is directly involved in the radial migration and maturation of neural precursors during embryonic cortical development (Burrows et al., 1997 (Burrows et al., , 2000 Kornblum et al., 1997; Caric et al., 2001; Ciccolini et al., 2005) , but its functional role in postnatal neural progenitor is not completely defined.
In the present study, we demonstrate that EGFR overexpression in nonmigratory cortical NG2 ϩ cells induces these cells to migrate from the SVZ into the SCWM, the hippocampus, and the RMS/OB after grafting. Our results indicate that increasing EGFR expression in neural progenitor cells to enhance their migratory potential may help to develop new transplantation therapies by optimizing cell engraftment in different brain regions.
Materials and Methods
Transgenic mice. The CNP-enhanced green fluorescent protein (EGFP) and ␤-actin-GFP transgenic mice (Tg ActbGFP) (stock number 003772; The Jackson Laboratory, Bar Harbor, ME) have been described previously Yuan et al., 2002; . Details on the generation and characterization of the CNPase-hEGFR transgenic mice have been reported previously (Ling et al., 2005) . Genotyping of these transgenic mice was performed by PCR (Ling et al., 2005) . Transgenic mice were backcrossed more than four generations onto C57BL/6 mice. In two lines of CNPase-hEGFR mice, including the one used here, no obvious defects in brain oligodendrocytes were detected. For example, there was no change in width of the adult corpus callosum. Consistent with CNP driving expression in oligodendrocytes, robust hEGFR expression in total brain and spinal cord lysates from adult brain was detected previously by using monoclonal anti-human EGFR antibody to probe Western blots after immunoprecipitation with a polyclonal anti-EGFR antibody (Ling et al., 2005) . In addition, hEGFR expression was detected in oligodendrocyte lineage cells of the white matter in both postnatal day 15 (P15) and adult CNPase-hEGFR mice (A. Aguirre and V. Gallo, unpublished observation). All animal procedures were performed according to the Institutional Animal Care and Use Committee of Children's National Medical Center and the National Institutes of Health guidelines.
Real-time PCR. Messenger RNA was extracted from postnatal day 8 whole brain and SVZ using the Micro-FastTrack kit for isolation of mRNA from small samples (Invitrogen, Carlsbad, CA). The mRNA was DNase treated (New England Biolabs, Ipswich, MA) according to the instructions of the manufacturer and purified with phenol chloroform. cDNA was generated as described previously (Ling et al., 2005) , and duplicate samples lacking reverse transcriptase were conducted to control for genomic DNA contamination. Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers (sense, 5Ј-ACCCAGAA-GACTGTGGATGG; antisense, 5Ј-GGAGACAACCTGGTCCTCAG; expected product size, 300 bp) were included in each reaction as a positive control for cDNA. For quantitative real-time PCR experiments, cDNA was used (as generated above), as were primers for known EGFR ligands: amphiregulin, betacellulin EGF, epiregulin, heparin-binding EGF, and transforming growth factor ␣ (TGF␣) (sequences available on request). Duplicate experiments with triplicate reactions were performed in an ABI Prism 7700 Sequence Detection System Cycler (Applied Biosystems, Foster City, CA) according to the instructions of the manufacturer. Briefly, 1 l of cDNA or water control was placed into a 50 l reaction volume containing 25 l of SYBR Green Master Mix (2ϫ concentration; Applied Biosystems) and volumes of primers that ranged between 0.5 and 9 l, depending on the optimal conditions for each primer set. The remaining volume comprised water. The thermal cycling conditions comprised an initial equilibration step at 60°C (2 min), a denaturation step at 95°C (10 min), followed by 40 cycles of 95°C (15 s) and 60°C (1 min). When applicable, cycle threshold (C t ) values were obtained from the point during amplification at which the fluorescent intensity was in the geometric phase, as determined by PE Applied Biosystems (Foster City, CA) analysis software. All PCR products were analyzed on a 2% agarose gel. When applicable, the ⌬C t values were determined for whole brain and SVZ, and relative ligand expression was calibrated to GAPDH expression (primers as above). Fold change of ligands in SVZ compared with whole brain were calculated using the established equation (K. Luvak, PE ABI Sequence Detector User Bulletin 2): 2 -⌬⌬ Ct , where C t is the cycle number at the chosen amplification threshold, ⌬C t ϭ C t(ligand) Ϫ C t(GAPDH) , and ⌬⌬C t ϭ ⌬C t(ϩ/Ϫ) Ϫ ⌬C t(ϩ/ϩ) .
SVZ explants migration assays. P8 brains from CNP-EGFP mice were dissected out and transferred to ice-cold HBSS medium (Invitrogen). The brains were cut in 200 m-thick sections, and only those sections containing the SVZ were selected for additional manipulation. The SVZ was dissected along the lateral wall of the lateral ventricles under a surgical microscope, and then cut into small pieces (50 -100 m in size) that were placed on top of 50% BD PuraMatrix Peptide Hydrogel (BD Biosciences, Franklin Lakes, NJ). Peptide Hydrogel was prepared following the manufacturer's recommendations. Briefly, 35 mm diameter cell inserts (0.4 m pore size; Corning, Corning, NY) were coated with Peptide Hydrogel diluted 1:1 with 1xPBS (pH7.4). After polymerization, the gel was equilibrated three times with neurobasal medium containing B27, N2 supplements, L-glutamine (0.5 mM) and penicillin-streptomycin (all from Invitrogen). Cultures were maintained in a humidified incubator at 5% CO 2 and 37°C for 4 d in vitro. SVZ explants were cocultured with heparin bead (Sigma, St Louis, MO) loaded with EGF (2 g/ml) and control (0.1% BSA; Sigma) proteins. Explants were symmetrically positioned in between EGF-and BSA-loaded beads (300 -400 m from each set of beads), using a graticulate with scale division. This configuration allowed the simultaneous analysis of EGFP ϩ cell migration with the two sets of beads. For direct quantification of cell migration, SVZ explants were subdivided into four quadrants, and the areas occupied by migrating cells in two of these quadrants (facing either BSA-or EGF-coated beads) were quantified by image analysis as previously described (Pozas et al., 2001) . The same results were also obtained by separately testing individual explants with EGF-and BSA-loaded heparin beads.
In a separate set of experiments, the original SVZ explants were scraped off the culture dish at 72 h days after plating, and CNP-EGFP ϩ cells that had migrated out of the explants and had remained attached to the dish were FACS-purified. These cells were then used to grow clonal neurospheres (5 cells/l) for 6 -7 d, and then plated in differentiation medium to determine their lineage potential .
Fluorescence activated cell sorting (FACS). FACS-purification of NG2
ϩ /EGFP ϩ and NG2 ϩ /GFP ϩ cells has been previously described in detail . Tissue from P8 CNP-EGFP, ␤-actin-GFP, CNP-hEGFR, or CNP-hEGFR/Tg ActbGFP mice was dissociated to a single cell suspension, followed by immunostaining for NG2 . To fluorescence-activated cell sorter (FACS) purify NG2 ϩ cortical cells transfected with an hEGFR or a constitutively active human EGFR (hEGFRviii) construct (see below), anti-NG2 (Chemicon, Temecula, CA), and anti-hEGFR (Biofluids, Camarillo, CA) antibodies were used in combination with appropriate R-phycoerytrin (PE)-conjugated and PE-cyanine 5.5 (Cy5.5)-conjugated secondary antibodies, respectively (Caltag, Burlingame, CA). To FACS purify NG2 ϩ cortical cells transfected with phosphorylated cytomegalovirus (pCMV)-internal ribosomal entry site (IRES)-GFP (mock-GFP), anti-NG2 antibodies and GFP expression were used . Cell suspensions were analyzed for light forward and side scatter using an FACStar plus instrument (Becton Dickinson, Franklin Lakes, NJ) .
Chemotaxis assays in Boyden chambers. FACS-purified NG2 ϩ cells were obtained from the SVZ or the cerebral cortex of P8 CNP-EGFP mice . Cortical transfected NG2 ϩ /GFP ϩ /hEGFR ϩ , and NG2 ϩ /GFP ϩ /hEGFR ϩ viii and NG2 ϩ /mock-GFP ϩ cells were FACS purified as described above. All NG2 ϩ cells were resuspended at 1 ϫ 10 6 cells/ml in stem cell medium (SCM) (serum-free DMEM/F-12) supplemented with N2 and B27 (Invitrogen) for chemotaxis assays. In vitro migration of NG2 ϩ cells was assessed using poly-L-lysine-, laminin-, vitronectin-, or fibronectin-coated (used at 5, 2, and 5 g/ml, respectively) polyvinylcarbonate-free membranes with 8 m pore size (Neuroprobe, Gaithersburg, MD). Assays were performed in modified Boyden chambers. Briefly, 25 l of a solution containing 1 ϫ 10 6 cells/ml in SCM was placed in the upper chamber. Growth factors, including EGF (10 ng/ml), TGF␣ (10 g/ml), basic FGF (bFGF) (10 g/ml), or plateletderived growth factor (PDGF) (10 g/ml) were all diluted in DMEM/ F-12 and added to the lower chamber in DMEM/F-12 or to both chambers when indicated. In the experiments in which EGFR blockers were used, cells were preincubated with the inhibitors for 30 min at 37°C in 5% CO 2 before loading in the top chamber. Blockers included the following:
(1) the cell-permeable, irreversible and selective inhibitor of EGFR tyrosine kinase activity PD168393 (4-[3(bromophenyl)-amino]-6-acrylamidoquinazoline), which does not inhibit other kinases (Calbiochem, La Jolla, CA); (2) selective anti-hEGFR (clone LA1, catalog #05-101) or anti-EGF-neutralizing antibodies (catalog #06-102) (both from Upstate, Charlottesville, VA), and (3) the arginine-glycine-aspartate (RGD) peptide inhibitor of integrin-ligand interactions (Calbiochem). After overnight incubation (12 h) at 37°C in 5% CO 2 , the upper surface of membranes was scraped free of cells and debris, and membranes were air dried, fixed, and mounted. Cells that had migrated through the pores and adhered to the membrane were analyzed under high-power light microscopy and counted in five to six adjacent high-power fields (HPFs) (area of HPF, 0.78 mm 2 ; area of each filter, 7.07 mm 2 ) in triplicate (three different membranes for each experimental condition). Experiments were repeated three times, and data were analyzed from a total of 45-54 fields from nine membranes for each experimental condition. Data were expressed as numbers of cells per HPF Ϯ SEM. Data were analyzed for statistical significance between groups by using the unpaired t test.
Bromodeoxyuridine pulse and terminal deoxynucleotidyl transferasemediated biotinylated UTP nick end labeling assays. FACS-purified NG2 ϩ cells were seeded (25,000 cells per well) in 24-well culture plates precoated with laminin. Cells were cultured in SCM for 12 h in the presence or absence of EGF (10 ng/ml). Cells were pulsed with 10 M bromodeoxyuridine (BrdU) for 12 h before fixation. BrdU immunostaining and terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) assay were performed as described previously .
Antibodies and immunohistochemistry. Freshly cut, floating tissue sections (50 m) from P8 mice were prepared as described previously . Primary antibody dilutions were as follows: 0.5 g/ml for the specific anti-hEGFR (Biofluids); 1:50 for the anti-EGFR (Upstate) and anti-BrdU (BD Biosciences); 1:100 for the anti-caveolin (Santa Cruz Biotechnology, Santa Cruz, CA); 1:200 for anti-EGF (Chemicon); and 1:500 for anti-NG2 antibody (Chemicon), anti-Ki-67 (Novocastra, Newcastle, UK), anti-␤-catenin (BD Biosciences), anti-N-cadherin (BD Biosciences), anti-caspase 3 (Cell Signaling Technology, Beverly, MA), anti-GFP (Clontech, Palo Alto, CA), and anti-GFAP (Sigma, St. Louis, MO). Nuclear staining was performed using TO-PRO (Invitrogen).
Western blot analysis. FACS-purified NG2 ϩ cells were used for protein extraction using lysis buffer [50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 0.1% 2-mercaptoethanol, and 1% Triton X-100, plus proteases inhibitor cocktail (Sigma)]. Protein samples (20 g) were separated on GENE Mate express Gels 4 -20% (ISC BioExpress, Kaysville, UT) and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). hEGFR, EGFR, and EGF bands were detected using an enhanced chemiluminescence substrate mixture (ECL Plus; Amersham Biosciences, Buckinghamshire, UK). A selective primary anti-human EGFR (Biofluids), anti-EGFR (Upstate), anti-EGF (Chemicon), and antiphosphorylated extracellular signal-regulated kinase (pERK) (Cell Signaling Technology) antibodies were used in combination with a secondary horseradish peroxidase conjugate (Jackson ImmunoResearch, West Grove, PA).
DNA constructs and transfection procedure. Cortical cell cultures were prepared from P8 Tg ActbGFP or from FVB/NxCB6 [wild type (wt)] mouse brains. Cortical tissue was dissociated to a single cell suspension and plated onto poly-L-lysine precoated 60 mm dishes at a density of 1.5 ϫ 10 6 cell/ml in DMEM/10% FCS medium for 12 h before transfection. For cell transfection, CMV promoter vectors containing the cDNA of the wild-type hEGFR (Upstate) and of the constitutive active EGFR (pLTR-EGFRviii) (Schmidt et al., 1998) were used. A pCMV-IRES-GFP (Clontech) vector was used as a mock plasmid in controls. All plasmid constructs were introduced into cultured cortical cells by Lipofectamine-mediated transfection (GTS, San Diego, CA), using 3 g of DNA and 10 l of liposomes in OptiMEM (Invitrogen). The duration of the transfection was 8 h. After transfection, the culture medium was changed to DMEM/10% FBS for 36 h, and cells were harvested and then processed for double immunostaining with anti-NG2 and antihEGFR antibodies. The anti-hEGFR antibody that was used specifically recognizes the wt and the constitutively active hEGFRs and does not react with the murine EGFR (Biofluids). Cells were then FACS purified as described above.
Transplantation and analysis of grafted cells. Wild-type P4 FVB/NxCB6 pups were used as recipients. Donor cells included the following: (1) FACS-purified P8 NG2 ϩ /GFP ϩ cells from the ␤-actin-GFP mouse strain ; (2) FACS-purified P8 SVZ or cortical NG2 ϩ cells from the CNP-hEGFR mouse strain (Ling et al., 2005) ; (3) FACS-purified P8 cortical NG2 ϩ /GFP ϩ cells from the CNP-hEGFR mouse strain crossed with the ␤-actin-GFP mouse strain (CNPhEGFR/Tg ActbGFP mouse); (4) cultured cortical NG2 ϩ /GFP ϩ cells from ␤-actin-GFP mice transfected with the hEGFR or the hEGFRviii construct (NG2 ϩ /GFP ϩ /hEGFR ϩ and NG2 ϩ /GFP ϩ /hEGFR ϩ viii, respectively); and (5) cultured cortical NG2 ϩ cells from FVB/NxCB6 mice transfected with the pCMV-IRES-GFP construct (NG2 ϩ /mock-GFP ϩ ). Immediately after FACS, cells were washed with DMEM plus 10%FCS and resuspended in DMEM at 20,000 cells/l. Microinjection was performed under deep hypothermia, and 1 l of the cell suspension was injected directly into the ventricles. In some experiments, trypan blue (0.1%) was added to the cell suspension to confirm targeting of injections. The injection was performed with a glass capillary pipette (100 -150 m outer diameter with beveled tip) driven by a Harvard Instruments (Murrieta, CA) micromanipulator. In the grafting experiments using donor cortical cells from the CNP-hEGFR mouse, cells were also stained with chloromethylbenzamido-DiI (Invitrogen), as recommended. Briefly, NG2
ϩ /CNP-hEGFR ϩ cells were incubated for 5 min with DiI (1 g/ml; Invitrogen) at 37°C and then placed on ice for 15 min. The reaction was stopped with basal DMEM medium, and cells were washed twice with DMEM. For migration and anatomical distribution studies, mice were maintained for 7-10 d after the cell graft and processed for immunohistochemistry as described previously . Cells derived from grafted NG2 ϩ /GFP ϩ cells or from transfected cells were readily visible under confocal microscopy in unstained tissue, using a 488 nm laser-line excitation. Cells derived from wt/NG2 ϩ /mock-GFP ϩ cells were visualized after anti-GFP immunostaining with an anti-GFP rabbit polyclonal antibody (IgG, 1:500; Clontech), as described previously . The percentages of total transplanted GFP ϩ or DiI ϩ cells found in striatum, SCWM, wall of the LV, SVZ, RMS, fimbria, OB, and hippocampus were quantified in three separate experiments as described below.
For analysis of cell differentiation 4 weeks after transplantation, neuronal-specific nuclear protein (NeuN), CNP, and GFAP antibodies were used as cell markers to identify neurons, oligodendrocytes, and astrocytes, respectively. For counting of cells derived from transplanted cortical NG2 ϩ /hEGFR ϩ /EGFP ϩ cells, EGFP ϩ cells were counted in different brain regions. Cell numbers were obtained by analyzing a total of 1850 cells in 300 sections (40 m thickness) from three different experiments (three different brains). Cell counting data in tissue sections were expressed as averages Ϯ SEM. Statistical analysis was performed by paired t test.
Microscopy and cell counting. An Olympus Optical (Melville, NY) BX60 fluorescence inverted microscope was used to visualize immunofluorescence in cultured cells. Images were acquired using a 40ϫ objective. For analysis in tissue sections, a Bio-Rad (Hercules, CA) MRC 1024 confocal laser-scanning microscope equipped with a krypton-argon laser and an Olympus Optical IX-70 inverted microscope were used to image localization of FITC (488 nm laser-line excitation; 522/35 emission filter), Texas Red (568 nm excitation; 605/32 emission filter), and Cy5 (647 excitation; 680/32 emission filter). Optical sections (Z ϭ 0.5 m) of confocal epifluorescence images were sequentially acquired using a 40ϫ [numerical aperture (NA), 1.35], a 60ϫ (NA, 1.40), or 100ϫ oil objective (NA, 1.35) with Bio-Rad LaserSharp version 3.2 software. Confocal Assistant 4.02 was used to merge images. Merged images were processed in Photoshop 7.0 (Adobe Systems, San Jose, CA) with minimal manipulations of contrast.
For cell counting in cultured cells, averages were obtained from three separate sets of cultures. In each culture, at least 10 separate microscopic fields (248 m 2 ) were analyzed. For GFP ϩ and DiI ϩ cells in tissue sections, cells were counted in the striatum, SCWM, wall of the LV, SVZ, RMS, fimbria, OB, and hippocampus 1 week after grafting. The anatomical distribution of GFP ϩ and DiI ϩ cells was analyzed in Z-series confocal scanning images [20 -30 m thickness; step size, 0.5 m between successive images of the same field (228 m 2 )]. Cell numbers were obtained by analyzing the entire brain after grafting, i.e., an average of 144 total tissue sections per brain (40 m thickness) from at least three to four independent grafting experiments (three to four different brains total). The total number of graft-derived cells per brain ranged between 1400 and 1600 for any of the transplanted cell populations . The number of cells found in each region was expressed as percentage of the total number of graft-derived cells found in each brain. Cell counting data in tissue sections are expressed as averages Ϯ SEM. Statistical analysis was performed by unpaired t test.
Results

EGF and EGFR expression in NG2
؉ progenitor cells We examined expression of EGFR and EGF in NG2 ϩ cells by immunostaining tissue sections of P8 CNP-EGFP mouse brains . A large percentage of NG2 ϩ cells in the SVZ, RMS, and SCWM expressed EGFRs (Fig. 1a-c) , but expression in cortical NG2 ϩ cells was undetectable ( Fig. 1d) . Virtually all NG2
ϩ cells of the SVZ were immunopositive for EGFR and its ligand EGF (Aguirre and Gallo, unpublished observation) . Western blot analysis of EGFR and EGF expression in FACS-purified NG2 ϩ cells showed that SVZ progenitors expressed much higher levels than their cortical counterpart (Fig. 1e,f ) . This pattern of EGFR and EGF expression in the SVZ and RMS was consistent with previously published data obtained by in situ hybridization and immunocytochemistry, respectively (Anton et al., 2004) . Real-time quantitative PCR analysis of P8 SVZ and P8 brain demonstrated that, under our experimental conditions, both heparin binding EGF and TGF␣ RNAs were expressed at detectable levels in both tissues. Amphiregulin was detected only in the SVZ, but betacellulin, EGF, and epiregulin were undetectable in both SVZ and brain (K. Monk, A. Aguirre, N. Ratner, and V. Gallo, unpublished observation). Altogether, these data show that EGFR and appropriate ligands are expressed in NG2 ϩ cells of the SVZ, RMS, and SCWM and therefore may play a role in the migration of this highly motile class of postnatal cells , as shown previously for VZ progenitors (Burrows et al., 1997) .
EGF promotes migration of SVZ NG2
؉ cells through EGFR activation To determine whether EGFRs are involved in SVZ NG2
ϩ cell migration, we placed SVZ explants from the CNP-EGFP mouse brain equidistantly (300 -400 m) from ectopic sources of EGF and BSA, i.e., between heparin beads soaked with either recombinant EGF or BSA. This configuration allowed the simultaneous analysis of EGFP ϩ cell migration with the two sets of beads ( Fig. 2a-c) . Under these conditions, a high percentage of EGFP ϩ cells had already migrated out of the explant toward the EGF-soaked beads during the first 24 h in culture (data not shown). At 72 h in culture, EGFP ϩ cells displayed very limited migration out of the explant toward BSA-heparin beads (Fig. 2a1-a6 ). Conversely, a large number of EGFP ϩ cells exhibited migration toward the EGFheparin beads (Fig. 2b1-b6 ). Direct quantification of cell migration at 72 h was performed by measuring the area occupied by migrating EGFP ϩ cells (Fig.  2c1,c2 ). This demonstrated a fivefold increase in EGF-stimulated migration compared with BSA (Fig. 2c2) . Approximately 70% of the EGFP ϩ cells that were migrating in the presence of EGF were NG2 ϩ ( Fig.  2b2-b4 ) . Furthermore, only EGFP ϩ cells that had migrated in the presence of EGF displayed a typical migratory morphology, with a small cell body and a thin cell process oriented toward the ϩ cells depends on the EGF concentration gradient. Cell migration was measured in the presence of EGF in the lower chamber (dark circle, 10 ng/ml). The addition of EGF in the upper chamber (1-10 ng/ml) progressively reduces directional cell migration induced by EGF in the lower chamber. Cell migration in the absence of EGF was also measured (white oval). Unpaired t test compared with EGF in the lower chamber only, *p Ͻ 0.001; n.s., not significant. All data are represented as averages Ϯ SEM of triplicate determinations in at least three independent experiments. b, The EGFR blocker PD168393 inhibits migration of NG2 ϩ cells toward EGF (10 ng/ml) in a dose-dependent manner. Cells were preincubated with the PD168393 inhibitor for 30 min before seeding the cells in microchemotaxis chambers. Migration was assayed after 12 h. Unpaired t test compared with EGF alone, *p Ͻ 0.001. All data are represented as averages Ϯ SEM of triplicate determinations in at least three independent experiments. c, The EGF-neutralizing antibody silences EGFR-associated signaling. Cells were preincubated with the EGF-neutralizing antibody (EGFNab; 2 g/ml) or rabbit IgG (2 g/ml) for 30 min, before stimulation with EGF (10 ng/ml). c1, Western blots using specific anti-phospho-EGFR and anti-EGFR antibodies and anti-phospho-PLC␥ antibodies. Incubation of freshly purified SVZ NG2 ϩ cells with anti-EGF neutralizing antibodies suppressed EGFR-associated signaling, as demonstrated by EGFR and PLC␥ phosphorylation. The membranes were reprobed to show that equal levels of proteins were loaded, as shown by the antibody against total EGFR and total PLC␥ (bottom panels). c2, Western blot using specific antibodies for pERK or total ERK. Incubation of purified SVZ NG2 ϩ cells with EGF caused ERK phosphorylation, which was blocked by pretreatment with the anti-EGF neutralizing antibody (top). The membrane was reprobed to show that equal levels of proteins were loaded, as shown by the antibody against total ERK (bottom). d, The EGF-neutralizing antibody (EGFNab) inhibits directional migration of NG2 ϩ cells induced by EGF. Cells were preincubated with EGF-neutralizing antibody (2 g/ml) or rabbit IgG (IgGab; 2 g/ml) for 30 min before stimulation with EGF (10 ng/ml). Migration was assayed after 12 h. Unpaired t test, EGF compared with no growth factors (No GFs), *p Ͻ 0.002; EGF ϩ IgGab and EGF ϩ EGFNab compared with EGF, NS and **p Ͻ 0.03, respectively. 4 mouse cultured in hydrogel and exposed to BSA (left, white dotted line) or EGF (right, yellow dotted line). Scale bar, 300 m. c2, Histograms illustrate quantification of cell migration in SVZ explants, shown as average Ϯ SEM of migrated area (in square micrometers). A total of 10 explants from three different experiments were analyzed. *p Ͻ 0.01. d-g, Cell migration was determined using microchemotaxis chambers (Boyden chambers). In all of the cases, data represent averages Ϯ SEM of triplicate determinations from three different experiments. HPF, 40ϫ magnification. d, Different growth factors were used in the lower chamber to stimulate migration in SVZ NG2 ϩ cells. Note that EGF has the strongest effect on NG2 ϩ cell migration. No GFs, No growth factors. Unpaired t test compared with no GFs, *p Ͻ 0.005, **p Ͻ 0.01; n.s., not significant. e, Cortical NG2 ϩ cells do not migrate in presence of EGF, but they do in the presence of bFGF and PDGF. Unpaired t test compared with no GFs, *p Ͻ 0.0002, **p Ͻ 0.0005. f, TGF␣ promotes migration of SVZ NG2 ϩ cells to a similar extent as EGF. Unpaired t test compared with no GFs, *p Ͻ 0.005, **p Ͻ 0.0001. g, Dose-response curve of the effect of EGF on SVZ NG2
ϩ cell migration shows that the maximal effect of EGF occurs at 10 -20 ng/ml. g2-g4, Example of SVZ NG2 ϩ cells that migrated through the filters with different concentrations of EGF. Scale bars, 50 m.
source of EGF (compare Figs. 2b2-b4,b6 with a6 ) . Finally, migratory EGFP ϩ cells were still multipotential, as determined by FACS purification and clonal analysis in vitro (supplemental Fig.  S1 , available at www.jneurosci.org as supplemental material). These results strongly suggest that EGF promotes migration of multipotential SVZ NG2 ϩ /EGFP ϩ cells. To determine the specificity of EGF in promoting migration of SVZ NG2 ϩ cells, we used Boyden microchemotaxis chambers to compare the migratory behavior of FACS-purified NG2 ϩ / EGFP ϩ cells from the SVZ and cortex in the presence of different growth factors (Fig. 2d,e) . After 12 h, the maximal migratory effect on SVZ cells was observed in the presence of EGF (Fig. 2d) . PDGF promoted cell migration to a lesser extent than EGF, and bFGF had no effect (Fig. 2d) . Conversely, cortical NG2 ϩ cells did not migrate in the presence of EGF, but they did when exposed to PDGF or bFGF (Fig. 2e) .
To investigate the ligand specificity of the EGF-mediated migration in SVZ NG2 ϩ cells, we exposed these cells to TGF␣, another EGFR ligand present in the postnatal/adult SVZ (Kornblum et al., 1997; Junier, 2000) . TGF␣ promoted chemoattraction to a similar extent as EGF (Fig. 2f ) . A dose-response curve of the effect of EGF on SVZ NG2
ϩ cell migration showed that maximal effects were observed between 10 and 20 ng/ml (Fig. 2g) . Consistent with other systems in which growth factors promote chemotaxis, concentrations higher than 20 ng/ml were ineffective (Fig. 2g1) (Facchiano et al., 2000) . Importantly, EGF did not modify the mitotic index (percentage of NG2 ϩ /BrdU ϩ cells, 33 Ϯ 3% EGF vs 27 Ϯ 2% control; p Ͼ 0.07, unpaired t test) (supplemental Fig. S2 , available at www.jneurosci.org as supplemental material) nor the rate of cell death (percentage of NG2 ϩ / TUNEL ϩ cells, 1.31 Ϯ 0.5% EGF vs 1.5 Ϯ 0.5% control; p Ͼ 0.92, unpaired t test) (supplemental Fig. S2 , available at www. jneurosci.org as supplemental material) of SVZ NG2 ϩ cells during the time of the assay. Altogether, these results demonstrate that the observed EGF-induced migration was not attributable to an increase in the number of NG2 ϩ cells produced during the assay but rather to a direct promigratory effect of EGF.
Because the presence of a concentration gradient of a ligand is essential to maintain cell migration, we wanted to demonstrate that disruption of the EGF gradient prevented SVZ NG2 ϩ cell migration. Therefore, we performed experiments in which the same concentration of EGF was added to both the lower and upper chambers of the Boyden assembly. As shown in Figure 3a , maximal cell migration was reduced in a dose-dependent manner by increasing concentrations of EGF added only to the upper chamber while maintaining the concentration of EGF in the lower chamber constant.
To verify that EGF-induced migration was directly mediated by the activation of EGFR, we first preincubated SVZ NG2 ϩ cells with the specific EGFR inhibitor PD168393 (Fry et al., 1998) before plating. After this treatment, cell migration assessed in Boyden chambers was reduced in a dose-dependent manner (Fig.  3b) . In a separate set of experiments, we used an EGFneutralizing antibody, which binds to the EGF/EGFR complex and inhibits EGFR dimerization (Johnson et al., 2005; Varley et al., 2005) . NG2 ϩ cells were preincubated with this antibody to suppress autocrine activation of EGFRs through EGF synthesized by NG2 ϩ cells themselves (Fig. 1) . The EGF-neutralizing antibody silenced EGFR activation in purified SVZ NG2 ϩ cells, as demonstrated by EGFR phosphorylation and by EGFRassociated phospholipase C ␥ (PLC␥) phosphorylation (Fig. 3c1) . Furthermore, the same EGF-neutralizing antibody also prevented EGF-induced ERK phosphorylation in purified SVZ
NG2
ϩ cells in culture (Fig. 3c2 ). After treatment with the EGFneutralizing antibody, NG2
ϩ cell migration was reduced by ϳ60% (Fig. 3d) .
Altogether, these results are consistent with the interpretation that EGF and EGFR promote SVZ NG2 ϩ cell migration.
EGFR and extracellular matrix components coparticipate to promote SVZ NG2
؉ cell migration It has been described previously that EGFR-mediated migration entails the association of extracellular matrix (ECM) components with cell surface integrins (Hintermann et al., 2001 ). To determine whether EGFR-mediated migration in NG2 ϩ cells involved the ECM, we performed our chemotaxis assay in the presence of different ECM components. All of the assays described in Figures  2 and 3, a, b , and e, were routinely performed with filters coated with laminin. Figure 4a shows that EGF promoted SVZ NG2 ϩ cell migration only when cells were placed in chambers with filters coated with ECM components (laminin, fibronectin, and vitronectin) but not with poly-L-lysine, indicating that the ECM plays an important role in EGF-induced migration of NG2 ϩ cells.
The RGD sequence of many ECM proteins, including fibronectin and vitronectin, has been shown to directly interact with cell surface receptor integrins (Buckley et al., 1999) . Synthetic RGD peptides can block such matrix-integrins interaction. To identify whether the ECM-dependent effects of EGF were mediated by integrins, SVZ NG2 ϩ cells were incubated with RGDS peptides before they were placed in the chemotaxis chamber. EGF-induced directional migration of NG2 ϩ cells on fibronectin-coated (Fig. 4b) or laminin-coated (data not shown) filters was blocked by RGDS peptides in a dose-dependent manner but not by the control peptide RGD, which does not bind to the functional integrin domain (Fig. 4b) . In all of the microchamber assays described above, cell viability was determined by using trypan blue before cell plating (data not shown) and by TUNEL after the assay. Cell viability was similar in all of the experimental conditions tested (data not shown). In conclusion, our results are consistent with the interpretation that EGFR and ECM components coparticipate to promote SVZ NG2 ϩ cell migration.
In vivo migration of grafted SVZ NG2 ؉ cells in the postnatal brain depends on EGFR activity
We have shown previously that SVZ NG2
ϩ cells isochronically transplanted into the P4 LV display extensive rostral and caudal ϩ /EGFP ϩ cells were FACS purified from the SVZ of P8 CNP-EGFP mice. a, EGF promotes directional migration in the presence of different extracellular matrix components but not in the presence of poly-L-lysine. Unpaired t test compared with no growth factors (No GFs), *p Ͻ 0.001; n.s., not significant. b, EGF-induced directional migration involves integrin proteins. NG2 ϩ cells were mixed with RGDS (integrin binding inhibitor, white squares) or RGD peptides (control peptide, dark squares) at the indicated doses, before loading onto the chambers. Cell migration with (10 ng/ml) or without EGF is indicated with black and white ovals, respectively. Unpaired t test, compared with EGF alone, *p Ͻ 0.001. migration in the postnatal brain . This process occurs after RMS development is completed (Pencea and Luskin, 2003) , indicating that dispersal of NG2 ϩ cells is not attributable to simple diffusion within the ventricle and subsequent integration into accessible areas, but rather to active migration. Furthermore, similar results were also obtained when grafting of NG2 ϩ cells was performed in older (P9 -P10) host mice (Aguirre and Gallo, unpublished observation) .
To define how EGFR may participate in this cell migration in vivo, we FACSpurified NG2 ϩ /GFP ϩ cells from P8 ␤-actin-GFP mice and preincubated them with the same EGF-neutralizing antibody used in our in vitro migration assays (Fig. 3c,d ) to neutralize autocrine EGF signaling. Control cells were incubated with an anti-IgG control antibody. Both anti-EGF and antiIgG-treated cells were grafted into the LV of P4 FVB/NxCB6 (wt) recipient mice. Figure 5 , a and d, shows results of experiments in which the migration pattern of anti-IgG-treated SVZ NG2 ϩ /GFP ϩ cells was analyzed 1 week after transplantation (1WAT). As demonstrated previously with cells not exposed to any antibody treatment , most of the anti-IgG-treated cells migrated rostrally into the RMS and caudally to the SCWM, but a sizeable percentage was also found in the hippocampus (Fig. 5b,d) . Conversely, when NG2 ϩ cells were preincubated with the EGF-neutralizing antibody, the majority of grafted cells only displayed very limited migration and were found in the periventricular tissue (Fig. 5c,d ). After exposure to the EGF-neutralizing antibody, migration of NG2 ϩ /GFP ϩ cells to the SCWM, OB, and hippocampus was severely reduced (Fig. 5d) ; instead, a significantly higher number of cells were found in the SVZ and in the fimbria and surrounding the wall of the LV (Fig. 5c,d ). NG2 ϩ /GFP ϩ cells that had not migrated were viable (i.e., TUNEL negative; data not shown) and appeared to be morphologically differentiated (Fig. 5c) . These results suggest that the EGFR may play an important role in NG2 ϩ cell migration from the SVZ into the RMS, OB, SCWM, and hippocampus.
EGFR overexpression converts cortical NG2
؉ cells from a nonmigratory to a migratory phenotype Our results demonstrate that cortical NG2 ϩ cells, differently from their SVZ counterpart, express low levels of EGFR and EGF and do not migrate in the presence of EGF (Figs. 1, 2) . These results are consistent with previous grafting experiments in which cortical NG2 ϩ cells isochronically transplanted into the LV displayed a very restricted migratory potential (Aguirre and Gallo, 2004).
To further define a causal relationship between EGFR expression and migratory potential of NG2 ϩ cells by using a different Figure 5 . EGF-dependent migration of grafted SVZ NG2 ϩ cells. NG2 ϩ /GFP ϩ cells were FACS purified from the SVZ of P8 Tg ActbGFP mice and transplanted into the LV of P4 wild-type host mice. Brains were analyzed 1WAT. GFP ϩ cells were visualized by fluorescence microscopy. a, Cells were treated with a control anti-IgG antibody before transplantation. Migrating GFP ϩ cells were found throughout the RMS (a2, a3) and in the OB (a4 ). Graft-derived GFP ϩ cells were also found in the SCWM (a1) and in the CA3 and stratum oriens (SO) of the hippocampus (b). c, FACS-purified NG2 ϩ /GFP ϩ cells were preincubated with the EGF-neutralizing antibody (EGFNab) before transplantation into the LV. Grafted NG2 ϩ /GFP ϩ cells treated with the EGF-neutralizing antibody did not migrate, and the majority of grafted cells were found attached to the parenchyma and in the ependymal layer of the LV (c1, c2). ϩ /hEGFR ϩ /GFP ϩ cells from cortical cultures transfected with the phEGFR construct. NG2 and hEGFR immunolabeling were scattered with PE-Cy5 (b2) and R-PE (b3), respectively. To scatter triple-positive (NG2 ϩ /hEGFR ϩ /GFP ϩ ) cells, the NG2 ϩ /GFP ϩ fraction (R3 box in b3) was double sorted using PE-Cy5.5 for NG2 and RPE for hEGFR (R4 box in b5) . Note that a significant percentage of NG2 ϩ /GFP ϩ cells expressed the hEGFR. All data are shown as means Ϯ SEM obtained from a total of three to four separate experiments in triplicate. c, Transfected, FACS-purified cortical NG2
ϩ /mock-GFP ϩ , NG2 ϩ /hEGFR ϩ /GFP ϩ , or NG2 ϩ /hEGFRviii ϩ /GFP ϩ cells were used in migration assays in chemotaxis chambers. Cell migration was assayed 12 h after seeding the cells in microchemotaxis chambers. Overexpression of the hEGFR or hEGFRviii confers migratory properties to the cells. Note that, in approach, we first overexpressed the human EGFR (CMVhEGFR) or the constitutively active human EGFR (CMVhEGFRviii) (Schmidt et al., 1998) in cultured cortical glial cells prepared from P8 ␤-actin-GFP mice to FACS purify NG2 ϩ / hEGFR ϩ /GFP ϩ and NG2 ϩ /hEGFRviii ϩ /GFP ϩ cells from these cultures. Figure 6a shows Western blot analysis and immunostaining of cultured cortical ␤-actin-GFP ϩ cells 36 h after transient transfection, before FACS purification. Western blot analysis demonstrated that transient transfection resulted in the expression of both the hEGFR and the hEGFRviii proteins, but higher levels of expression were observed with the hEGFR (Fig.  6a1) . Expression of the hEGFR was undetectable in cortical cultures of wt mice transfected with a pCMV-IRES-GFP construct (Fig. 6a1, pmock) . A significant percentage (9 -10%) of cortical NG2 ϩ cells present in the mixed glial cultures were transfected and expressed the hEGFR (Fig. 6a2-a6, arrows) or the hEGFRviii (data not shown) in the cell membrane, as demonstrated by immunostaining with anti-hEGFR antibodies.
We then FACS purified NG2 ϩ /hEGFR ϩ /GFP ϩ and NG2 ϩ / hEGFRviii ϩ /GFP ϩ cells (Fig. 6b1-b5 ) to perform in vitro and in vivo migration assays. Figure 6c shows that expression of the hEGFR in purified cortical NG2 ϩ /GFP ϩ cells increased by approximately fourfold the migratory potential of these progenitors in the presence of EGF in vitro compared with mock-transfected cells. All of the NG2 ϩ /GFP ϩ cells that had migrated in the presence of EGF were hEGFR ϩ (Fig. 6d4 -d9) . The increased migratory potential of cortical NG2 ϩ cells transfected with the hEGFR was confirmed by overexpression of the hEGFRviii. Figure 6c shows that FACS-purified cortical NG2 ϩ /hEGFRviii ϩ /GFP ϩ cells displayed a higher migration than mock-transfected cells, in both the absence and presence of EGF. As demonstrated for SVZ NG2 ϩ cells (Fig. 3a) , the presence of EGF in both the lower and upper chambers prevented cell migration also in cortical NG2 ϩ / hEGFR ϩ /GFP ϩ cells (Fig. 6e) . Under these conditions, NG2 ϩ / hEGFR ϩ /GFP ϩ cell migration was ϳ50% of that observed in the absence of EGF, indicating that overexpression of the hEGFR by itself promotes migration of cortical NG2 ϩ cells. Finally, both the EGFR inhibitor PD168393 and the neutralizing antibodies for EGFR and EGF prevented migration of cortical NG2 ϩ /GFP ϩ / hEGFR ϩ cells (Fig. 6f ) . To demonstrate that cortical NG2 ϩ /GFP ϩ /hEGFR ϩ cells also migrate in vivo, we grafted these transfected cells into the LV of P4 wt mice. Mock-transfected NG2 ϩ /GFP ϩ cells did not migrate and were found mostly surrounding the wall of the LV, the SVZ, and the fimbria (Fig. 7a,b,i) . Conversely, NG2 ϩ /GFP ϩ /hEGFR ϩ cells displayed extensive rostral and caudal migration (Fig. 7c-f,i) . At 1WAT, a large percentage of graft-derived NG2 ϩ /GFP ϩ / hEGFR ϩ cells were found in the SCWM, RMS, OB, and hippocampus (Fig. 7c-f,i) . These cells continued to express the hEGFR at 1WAT, as demonstrated by immunostaining with a selective anti-hEGFR antibody (Fig. 7h1-h4 , example of cells in SCWM).
NG2
؉ cells from the cerebral cortex of the CNP-hEGFRoverexpressing mouse display a migratory phenotype To further investigate the role of the EGFR in NG2 ϩ cell migration, we used a transgenic mouse in which the hEGFR was expressed in multipotential progenitors and in cells of the oligodendrocyte lineage under the control of the CNP promoter (CNP-hEGFR mouse) (Ling et al., 2005) . We first analyzed expression of the hEGFR in cortical NG2 ϩ cells of this mouse at P8. Only cortical NG2 ϩ cells from the CNP-hEGFR mouse expressed high levels of the hEGFR, whereas the same cell population from a C57B6 (wt) mouse did not (Aguirre and Gallo, unpublished observation) .
To obtain additional direct evidence that EGFRs are involved in NG2 ϩ cell migration in vivo, we FACS purified cortical NG2 ϩ cells from the CNP-hEGFR mouse, in which all NG2 ϩ cells constitutively expressed the hEGFR. When FACS-purified P8 NG2 ϩ /CNP-hEGFR ϩ cells were transplanted into the LV of P4 wt mouse brains, they displayed extensive rostral and caudal migration at 1WAT (Fig. 8) . Importantly, the migration pattern and distribution of the grafted cells was very similar to that observed with wt SVZ NG2 ϩ cells (Fig. 5 ) or with NG2
ϩ /hEGFR ϩ /GFP ϩ cells (Fig. 7) . Also, NG2 ϩ /CNPhEGFR ϩ cortical cells migrated to the SCWM (Fig. 8a) , through the RMS into the OB (Fig. 8a) , and to the hippocampus (Fig.  8c,d ). The majority of graft-derived cells migrating through the RMS were still NG2 ϩ (Fig. 8b ) , indicating that the original progenitor phenotype was maintained in grafted NG2
ϩ cells overexpressing the hEGFR. In parallel grafting experiments, it was confirmed that, as demonstrated previously in an independent study , grafted wt cortical NG2 ϩ cells displayed very limited migration (Fig. 8e ) (supplemental Fig. S3 , available at www.jneurosci.org as supplemental material).
To define the differentiation potential of cortical NG2 ϩ / hEGFR ϩ cells, we FACS purified cortical NG2 ϩ /CNP-hEGFR ϩ / GFP ϩ cells from a P8 CNP-hEGFR/Tg ActbGFP mouse and grafted these cells using the same transplantation paradigm used in the experiment shown in Figure 8 . These GFP ϩ cells displayed the same migration pattern shown for NG2 ϩ /CNP-hEGFR ϩ cells (Fig. 8 ) and maintained NG2 expression while they were migrating throughout the RMS (Fig. 9a) . Analysis with a variety of cell markers demonstrated that, in all of these regions, the vast majority of graft-derived CNP-hEGFR ϩ /GFP ϩ cells at 1WAT were GFAP ϩ astrocytes (Fig. 9c) or CNP ϩ oligodendrocytes (Fig.  9d) . Interestingly, the percentage of astrocytes generated in the SCWM after transplantation of cortical NG2 ϩ /CNP-hEGFR ϩ / GFP ϩ cells was significantly higher than with wt cells, whereas the percentage of oligodendrocytes was lower (Fig. 9b) .
Analysis of the graft-derived CNP-hEGFR ϩ and wt GFP ϩ cells demonstrated that their proliferation rate was similar [percentage of Ki-67 ϩ cells, 11.0 Ϯ 2.4% for wt (n ϭ 223) and 13.6 Ϯ 3.5 for CNP-hEGFR ϩ (n ϭ 285) cells, respectively]. Im-4 cortical NG2 ϩ /hEGFRviii ϩ /GFP ϩ cells, migration is not modified by EGF, confirming the constitutive activity of the hEGFRviii construct. Unpaired t test, *p Ͻ 0.001, **p Ͻ 0.002, ***p Ͻ 0.01. For the phEGFRviii, the difference between EGF and no EGF was not significant. d, Images of migrated cells in chemotaxis chamber immunostained with anti-hEGFR antibodies 12 h after plating. Cortical NG2 ϩ /hEGFR ϩ /GFP ϩ (d4 -d9) but not NG2 ϩ /mock-GFP ϩ cells (d1-d3) that had migrated through the filters expressed the hEGFR. e, Migration of cortical NG2 ϩ /hEGFR ϩ /GFP ϩ cells is inhibited by adding EGF to the upper chamber. Migration was assayed 12 h after seeding the cells in the microchemotaxis chambers. Unpaired t test compared with EGF in lower chamber only, *p Ͻ 0.01. f, EGF-induced migration of cortical NG2
ϩ /hEGFR ϩ /GFP ϩ cells was inhibited by the EGFR blocker PD168393 and by the EGFR-and EGF-neutralizing antibodies (EGFRNab and EGFNab, respectively). Cells were preincubated with EGFNab (2 g/ml), rabbit IgG (2 g/ml), or the PD168393 inhibitor (0.7 nM) for 30 min before stimulation with EGF (10 ng/ml). Migration was assayed after 12 h. Unpaired t test (compared with EGF or EGFRNab compared with IgGab), *p Ͻ 0.01, **p Ͻ 0.0003, ***p Ͻ 0.005; n.s., not significant. Scale bars, 50 m.
portantly, when grafted brains were analyzed 3 months after transplantation of NG2 ϩ /CNP-hEGFR ϩ /GFP ϩ cells, no evidence for tumor formation was found, as determined by hematoxylin and eosin staining (Aguirre and Gallo, unpublished observation) .
Discussion
The identification of cellular and molecular signals that promote proliferation, migration, and survival of postnatal neural progenitors is a priority in designing approaches for cell transplantation-based therapies (Bjorklund and Lindvall, 2000; Lindvall et al., 2004 ). The present study shows that multipotential NG2 ϩ progenitor cells offer a unique opportunity to devise cell transplantation strategies in the CNS, because these cells are found in different areas of the brain, in which they display distinct migratory and lineage potentials. By combining in vitro and in vivo studies, we demonstrate that endogenous EGFR expression is causally related to the different migratory potential that NG2 ϩ progenitor cells display in distinct brain regions. We also show that enhancing EGFR expression in nonmigratory NG2 ϩ cells that otherwise express lower levels of this receptor causes a conversion to a migratory phenotype and promotes their dispersal into different regions of the brain after transplantation.
Previous studies have demonstrated that neural progenitor cells from the postnatal/adult SVZ can migrate to different brain regions, i.e., rostrally through the RMS to the OB (Law et al., 1999; Alvarez-Buylla et al., 2000) , and radially/caudally to the SCWM (Kakita and Goldman, 1999; Suzuki and Goldman, 2003) . Under pathological conditions, SVZ progenitors display additional migration patterns. In the ischemia brain injury model, after exogenous EGF and FGF-2 application, Mash1 ϩ multipotential neural progenitors migrate from the SVZ to the hippocampus, in which they terminally differentiate to interneurons (Nakatomi et al., 2002) . NG2 ϩ progenitor cells in the early postnatal SVZ are highly proliferative and express cellular properties that correspond to the adult type C cells, including Mash1 . When these cells were transplanted into the LV, they migrated rostrally and caudally to the OB and SCWM, respectively, but also to the hippocampus, in which they generated inhibitory interneurons (Aguirre and Gallo, 2004; Aguirre et al., ϩ /GFP ϩ cells were FACS purified. FACS-purified wt/NG2 ϩ /mock-GFP ϩ cells were transplanted in the LV of P4 wt host mice. Brains were analyzed at 1WAT. Graft-derived wt/mock-GFP ϩ cells were visualized by fluorescence microscopy after anti-GFP immunostaining. Cortical wt/mock-GFP ϩ cells displayed very restricted migration, with a small percentage of graft-derived cells found in the SCWM (a1). The majority of the graft-derived wt/mock-GFP ϩ cells were found in the parenchyma, in the fimbria (a2), and in the ependymal layer of the LV (a3). b, No cells were observed in the OB. c, Cortical glial cultures from Tg ␤-actin-GFP mice were transfected with a wild-type hEGFR (phEGFR), and Tg ␤-actin-GFP ϩ /NG2 ϩ /hEGFR ϩ cells were FACS purified and transplanted into the LV as described in a. Brains were analyzed 1WAT. Graft-derived hEGFR ϩ /GFP ϩ cells were found in the RMS (c2) and in the OB (d1). hEGFR ϩ /GFP ϩ cells were also found in the SCWM (c1) and in the hippocampus (e, f ). g, h, Immunostaining with a selective anti-hEGFR antibody shows that graft-derived Tg ␤-actin-GFP ϩ /hEGFR ϩ cells in SCWM (h1-h4 ), but not wt/mock-GFP ϩ cells in the same brain region (g1-g4 ), express the hEGFR at 1WAT. i, Histograms represent percentages of total graftderived cells found in each region, including striatum (STR), SCWM, fimbria (FIM), LV, SVZ, RMS, OB, and hippocampus (HIP) at 1WAT. These percentages were obtained from counting the cells found in each region and the total cells found in each brain after grafting. Blue bars are cells derived from grafted wt/NG2 ϩ /mock-GFP ϩ cells, and red bars indicate cells derived from grafted Tg ␤-actin-GFP ϩ /NG2 ϩ /hEGFR ϩ cells. Dotted lines depict the hippocampus (a-e). Scale bars: a, b, c, d1, e, f, 300 m; a1-a3, c1, c2, d2, e1, f1, g1-g4, h1-h4 EGF and EGFRs are expressed in the SVZ, RMS, and hippocampus (Seroogy et al., 1995; Anton et al., 2004; Fox and Kornblum, 2005) . EGF is the best characterized mitogen for SVZ neural progenitor cells (Kuhn et al., 1997; Doetsch et al., 1999 Doetsch et al., , 2002 Gritti et al., 1999) . Intraventricular injection of EGF into the adult SVZ promotes progenitor proliferation as well as migration out of the lateral wall (Craig et al., 1996) , indicating that EGF and EGFRs may play a dual role in SVZ progenitor development. Our results indicate that both EGFRs and EGF are expressed at higher levels in NG2 ϩ progenitor cells of the SVZ than in cortical NG2 ϩ cells, indicating that autocrine activation of EGFRs is likely to occur in SVZ NG2 ϩ cells (Junier, 2000) . In the rodent brain, mobilization and migration of SVZ progenitors into the SCWM is still occurring during the first postnatal week (LeVine and Goldman, 1988; Marshall and Goldman, 2002; Kakita et al., 2003; Zerlin et al., 2004) . Therefore, the finding that EGFRs and EGF are highly expressed in NG2 ϩ cells that display a migratory phenotype are consistent with the idea that EGFRs could regulate migration of these cells out of the postnatal SVZ.
In the present study, we demonstrate marked differences in the migratory potential of SVZ versus cortical NG2 ϩ cells and a functional role for EGFRs in SVZ NG2 ϩ cell migration. EGF stimulates SVZ NG2 ϩ cell migration by a concentrationdependent gradient mechanism but is ineffective on cortical cells. Inhibition of EGFR activation by using either a receptor blocker or an EGF-neutralizing antibody prevents migration of SVZ NG2 ϩ cells. Finally, EGF-induced migration of NG2 ϩ cells is likely to involve integrin-ECM protein interactions (Lin and Bertics, 1995; Hintermann et al., 2001 ) because (1) it only occurs in the presence of laminin, fibronectin, or vitronectin and (2) is prevented by a peptide inhibitor of the integrin-ECM binding site. These results are consistent with previous findings showing that interactions between EGF and integrin signaling play an important role in supporting cell migration (Lin and Bertics, 1995; Moro et al., 1998; Xie et al., 1998) .
Previous studies revealed a role for the EGFR in radial neural progenitor migration in the developing telencephalon (Burrows et al., 1997; Caric et al., 2001; Ciccolini et al., 2005) . To demonstrate a function for EGFRs in SVZ tangential and radial/caudal migration in vivo, we used a previously established transplantation paradigm of early postnatal NG2 ϩ cells FACS purified from the SVZ and the cerebral cortex. Grafted SVZ NG2 ϩ progenitor cells migrate extensively into the postnatal RMS, OB, SCWM, and hippocampus, whereas cortical NG2 ϩ cells display very restricted migration dependent, and (3) prevented by blockage of the EGFR. We then used two different approaches to demonstrate that enhancement of EGFR expression increased the migratory potential of cortical NG2 ϩ cells in vivo. First, we transplanted transfected cortical NG2 ϩ /hEGFR ϩ cells into the early postnatal LV, and, second, we grafted cortical NG2 ϩ cells FACS purified from a transgenic mouse overexpressing the hEGFR under the CNP promoter (Ling et al., 2005) . Previous analysis from our laboratory demonstrated that all NG2 ϩ cells express the CNP gene . Both approaches used in the present study gave very similar results, i.e., a few days after transplantation, graftderived cortical cells were found in the SCWM and hippocampus and in numbers similar to those observed after transplantation of SVZ NG2 ϩ cells. Furthermore, as demonstrated previously with SVZ NG2 ϩ cells , a large percentage of graft-derived cells were also found migrating through the RMS into the OB. The increased percentages of cells found in these regions was not attributable to an increased rate of cell proliferation of the grafted NG2 ϩ /hEGFR ϩ cells, as demonstrated by (1) similar anti-Ki-67 staining in graft-derived control and hEGFR ϩ cells, and (2) the finding that increased percentages of graft-derived hEGFR ϩ cells in specific brain regions (i.e., OB, RMS, SCWM, and hippocampus) consistently corresponded to a proportional decrease in those regions from which these cells were migrating (i.e., SVZ, fimbria, and lateral wall). These results are consistent with the interpretation that, in our experimental model, EGFRs are necessary for NG2 ϩ cell migration in the postnatal brain. It appears that unique interactions between cellular EGFRs and the tissue environment play a crucial role in directing NG2 ϩ cell migration to different brain regions.
Cortical NG2 ϩ cells can generate neurons, oligodendrocytes, and astrocytes in vitro , and a small percentage of cortical NG2 ϩ cells express NeuN and other neuronal markers in situ (Dayer et al., 2005) . In the present study, analysis of graft-derived cells demonstrated that, although cortical NG2 ϩ /CNP-hEGFR ϩ cells migrate similarly to wild-type SVZ NG2 ϩ cells , they only generate astrocytes and oligodendrocytes in OB, SCWM, and hippocampus but do not generate neurons. This finding is consistent with previous studies showing that overexpression of the EGFR promotes a gliogenic fate in neural progenitor cells (Burrows et al., 1997 (Burrows et al., , 2000 Caric et al., 2001; Sun et al., 2005) .
EGFR overexpression in SVZ progenitor cells might cause brain tumors, which may derive from brain progenitor/stem cells (for review, see Fomchenko and Holland, 2005) . Oligodendrogliomas, which constitute 20% of glial tumors, and astrocytomas are correlated with increased EGFR signaling. In oligodendrogliomas, EGFR is frequently expressed at high levels; in astrocytomas, EGFR expression is associated with high-grade tumors and is associated with EGFR amplification or mutation (Libermann et al., 1985; Wong et al., 1992; Smith et al., 2001) . When modeled in mice, only v-erb, a constitutively active allele, is transforming, whereas EGFR is transforming only in the presence of ligand (Nishikawa et al., 1994; Holland et al., 1998; Weiss et al., 2003) . In our model, a wild-type EGFR allele unlikely to cause transformation is expressed, and ligand availability should determine when and where the receptor is activated (Ling et al., 2005) . Supporting the lack of transformation by the wild-type EGFR allele, when we aged a cohort of 30 CNP-hEGFR mice, none developed brain tumors, and mice died with the same kinetics as wild-type mice (Ling et al., 2005) . Furthermore, we did not observe tumor formation in host mouse brains up to 3-4 months after grafting NG2 ϩ /CNP-hEGFR ϩ cells. In conclusion, our findings indicate that EGFR expression plays an important role in promoting migration of SVZ neural progenitors and that manipulation of EGFR expression can convert neural progenitors from a nonmigratory to a migratory phenotype in the postnatal brain. Our studies will not only help understanding how intrinsic properties and specific cellular environments cooperate to promote cell migration and differentiation, but will also lead to optimizing the use of neural progenitors for therapeutic approaches in the damaged brain. 
